The in silico modeling of individual isothiocyanates with molecular cancer targets may suggest the potential inhibition of NF-κB, β-catenin, and NRF2 proteins, but additional in vitro and in vivo experiments are needed to validate these effects. The gene discussed is NFE2L2; the disease is cancer.